Results 41 to 50 of about 3,125,328 (279)

RRM1 is mediated by histone acetylation through gemcitabine resistance and contributes to invasiveness and ECM remodeling in pancreatic cancer

International Journal of Oncology, 2023
The invasiveness of pancreatic cancer and its resistance to anticancer drugs define its malignant potential, and are considered to affect the peritumoral microenvironment. Cancer cells with resistance to gemcitabine exposed to external signals induced by
H. Ono, Yoshiki Murase, Hironari Yamashita, Tomotaka Kato, D. Asano, Yoshiya Ishikawa, Shuichi Watanabe, H. Ueda, K. Akahoshi, K. Ogawa, A. Kudo, Y. Akiyama, Shinji Tanaka, M. Tanabe   +13 more
semanticscholar   +1 more source

DNA methylation-independent reversion of gemcitabine resistance by hydralazine in cervical cancer cells. [PDF]

PLoS ONE, 2012
BACKGROUND: Down regulation of genes coding for nucleoside transporters and drug metabolism responsible for uptake and metabolic activation of the nucleoside gemcitabine is related with acquired tumor resistance against this agent.
Myrna Candelaria, Erick de la Cruz-Hernandez, Lucia Taja-Chayeb, Enrique Perez-Cardenas, Catalina Trejo-Becerril, Aurora Gonzalez-Fierro, Alma Chavez-Blanco, Ernesto Soto-Reyes, Guadalupe Dominguez, Jaenai E Trujillo, Jose Diaz-Chavez, Alfonso Duenas-Gonzalez   +11 more
doaj   +1 more source

Possible Role of Cytochrome P450 1B1 in the Mechanism of Gemcitabine Resistance in Pancreatic Cancer

Biomedicines, 2021
Patient-derived xenograft models reportedly represent original tumor morphology and gene mutation profiles. In addition, patient-derived xenografts are expected to recapitulate the parental tumor drug responses.
Erica Yada, Rika Kasajima, Atsushi Niida, Seiya Imoto, Satoru Miyano, Yohei Miyagi, Tetsuro Sasada, Satoshi Wada   +7 more
doaj   +1 more source

Increased mitochondria are responsible for the acquisition of gemcitabine resistance in pancreatic cancer cell lines

Cancer Science, 2023
Pancreatic ductal adenocarcinoma has a particularly poor prognosis as it is often detected at an advanced stage and acquires resistance to chemotherapy early during its course.
H. Masuo, K. Kubota, A. Shimizu, T. Notake, S. Miyazaki, T. Yoshizawa, H. Sakai, H. Hayashi, Y. Soejima   +8 more
semanticscholar   +1 more source

Combination therapy with gossypol reveals synergism against gemcitabine resistance in cancer cells with high BCL-2 expression. [PDF]

PLoS ONE, 2012
Although gemcitabine is highly active in several cancer types, intrinsic and acquired drug resistance remains a major challenge. Overexpression of Bcl-2 has been associated with gemcitabine resistance.
Foong Ying Wong, Natalia Liem, Chen Xie, Fui Leng Yan, Wing Cheong Wong, Lingzhi Wang, Wei-Peng Yong   +6 more
doaj   +1 more source

MiR-17- 5p/RRM2 regulated gemcitabine resistance in lung cancer A549 cells

Cell Cycle, 2023
The main objective of this study is to investigate the regulatory roles of the miR-17-5p/RRM2 axis in A549/G+ cells’ gemcitabine resistance. The cell viability was determined using CCK8 and clonogenic assays. Gene expression level analysis by RT-qPCR and
Xuan Ma, Tianyu Fu, Zhi-Yin Ke, Shen-Lin Du, Xue-Chun Wang, Ning Zhou, M. Zhong, Yong-Jun Liu, Ai-Ling Liang   +8 more
semanticscholar   +1 more source

Extracellular Vesicle-Loaded Oncogenic lncRNA NEAT1 from Adipose-Derived Mesenchymal Stem Cells Confers Gemcitabine Resistance in Pancreatic Cancer via miR-491-5p/Snail/SOCS3 Axis

Stem Cells International, 2023
It is becoming increasingly evident that key mechanisms of mesenchymal stem cell (MSC) efficacy appear to associate with paracrine activities, and the delivery of cargos through extracellular vesicles (EVs) controls the mechanistic actions of MSCs. Thus,
Rongxiang Wu, Zhan Su, Lei Zhao, Ruifeng Pei, Yiren Ding, Deqiang Li, Shuo Zhu, Lu Xu, Wei Zhao, Wuyuan Zhou   +9 more
semanticscholar   +1 more source

Chemoresistance Transmission via Exosome-Transferred MMP14 in Pancreatic Cancer

Frontiers in Oncology, 2022
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest malignancies. Gemcitabine is the most commonly used chemotherapy for the treatment of PDAC, but the development of drug resistance still remains challenging.
Xinyuan Li, Kai Li, Mengmeng Li, Xiaoyu Lin, Yu Mei, Xuemei Huang, Huanjie Yang   +6 more
doaj   +1 more source

Irbesartan overcomes gemcitabine resistance in pancreatic cancer by suppressing stemness and iron metabolism via inhibition of the Hippo/YAP1/c-Jun axis

Journal of experimental & clinical cancer research : CR, 2023
Background Chemoresistance is the main reason for the poor prognosis of pancreatic ductal adenocarcinoma (PDAC). Thus, there is an urgent need to screen out new targets and compounds to reverse chemotherapeutic resistance.
Tianxing Zhou, Yongjie Xie, Xupeng Hou, Weiwei Bai, Xueyang Li, Ziyu Liu, Quan Man, Jing-yan Sun, Danqi Fu, Jingrui Yan, Zhaoyu Zhang, Yifei Wang, Hongwei Wang, Wenna Jiang, Song Gao, Tiansuo Zhao, Antao Chang, Xiuchao Wang, Hongxia Sun, Xiu-feng Zhang, Shengyu Yang, Chongbiao Huang, J. Hao, Jing Liu   +23 more
semanticscholar   +1 more source

Exosomal ACADM sensitizes gemcitabine-resistance through modulating fatty acid metabolism and ferroptosis in pancreatic cancer

BMC Cancer, 2023
This study aimed to evaluate the potential of exosomes from cancer cells to predict chemoresistance in pancreatic cancer (PC) and explore the molecular mechanisms through RNA-sequencing and mass spectrometry.
Yuhan Yang, Haitao Gu, Kun-dong Zhang, Zengya Guo, Xiaofeng Wang, Qingyun Wei, Ling-Ling Weng, Xueying Han, Yanhong Lv, M. Cao, P. Cao, Chen Huang, Z. Qiu   +12 more
semanticscholar   +1 more source